Suzhou, China

Xiaoting Zhai

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Jiangsu, CN (2021)
  • Suzhou, CN (2020 - 2024)

Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
9 patents (USPTO):

Title: The Innovative Contributions of Inventor Xiaoting Zhai

Introduction

Xiaoting Zhai is an esteemed inventor based in Suzhou, China, recognized for his significant contributions to the pharmaceutical field. With a remarkable portfolio of 9 patents, Zhai has focused on the development of crystalline forms of ozanimod, which show promise for treating autoimmune diseases, including multiple sclerosis and ulcerative colitis. His groundbreaking work is highly regarded in drug development circles.

Latest Patents

Zhai's latest patents include innovative crystalline forms of ozanimod, specifically crystalline forms CS9, CS10, and CS11. These crystalline forms are lauded for their enhanced solubility, stability, hygroscopicity, and processability, making them valuable in the preparation of ozanimod drug products. Additionally, Zhai has patented processes for the preparation of both ozanimod and ozanimod hydrochloride, which share similar therapeutic applications. The advancements represented in his patents provide new and better options for drug developers aiming to create effective treatments for autoimmune disorders.

Career Highlights

Throughout his career, Zhai has made notable contributions while working for reputable companies such as Receptos, Inc. and Crystal Pharmaceutical (Suzhou) Co., Ltd. His expertise in drug formulation and development has resulted in patents that push the boundaries of pharmaceutical innovation.

Collaborations

Zhai has collaborated with talented individuals in his field, including Minhua Chen and Yanfeng Zhang. These partnerships have undoubtedly fostered the exchange of ideas and boosted the advancement of pharmaceutical technology and product development.

Conclusion

Xiaoting Zhai stands out as a key innovator in the pharmaceutical industry. With a focus on developing novel crystalline forms of ozanimod, his efforts will undoubtedly continue to impact medication options available for individuals suffering from autoimmune diseases. His work not only enhances therapeutic effectiveness but also emphasizes the ongoing need for innovation in drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…